The Biden administration released their plan to address inflation and subsequently high drug prices and AARP reported that Part D spending on the top 10 brand drugs between 2016-2020 was more than five times the cost of developing a successful drug.

House Energy and Commerce leaders released a bipartisan legislative package with various drug spending provisions and the Senate Commerce Committee held a hearing on PBM anticompetitive practices.

The FDA found 1 in 4 drug manufacturers fail to submit or submit late status reports for post-marketing clinical trials and IQVIA released their annual report on drug usage and spending trends.

The Senate and House Diabetes Caucuses released their insulin pricing priorities.

CMS finalized their coverage determination for Aduhelm and MedPAC met to discuss Part B and D spending and pricing trends.

The House passed the Affordable Insulin Now Act 220-193.

HHS plans to study patients' understanding of an accelerated approval disclaimer, meanwhile consumer advocacy groups are urging Congress to use their march-in rights on at least six expensive drugs.

The Senate Finance Committee and House Energy and Commerce's Health Subcommittee held hearings to discuss policy proposals to lower drug costs.

President Biden signed the omnibus appropriations bill and the Senate Finance Committee will hold a hearing on prescription drug costs.

President Biden urged Congress to pass Medicare negotiation in his State of the Union and lawmakers wrote to PhRMA CEO Ubl on why manufacturers raised prices so significantly this past January.

In the weeks following the release of the proposed rule, CIDSA asked its expert panel to review the proposed rule to determine its potential impact.

The FTC has requested information regarding the impact of PBM practices on patients and stakeholders and Oregon withdrew their request for a closed formulary.

Senator Warnock introduced new legislation to cap the price of insulin for patients and the FTC held a vote on conducting an investigation into PBM practices.

The Senate confirmed Robert Califf as the new FDA Commissioner and IQVIA released a new analysis of global pharmaceutical R&D trends

CIDSA recognizes the proposed coverage determination will ensure appropriate access to treatment while limiting Medicare spending.

President Biden announced he would be willing to divide the Build Back Better Act to gain full Democratic support; HHS and CBO released individual reports on prescription drug affordability and spending, use, and prices, respectively.

CMS announced their proposal to cover Aduhelm with a Coverage with Evidence Development (CED) and Patients for Affordable Drugs released a report on prices hikes that have occurred already in 2022.

HHS Secretary Becerra requested CMS revisit the Part B premium hike in the wake of Aduhelm's price decrease and a drug price watching reported that launch prices are increasing faster than price hikes.

The Build Back Better Act was pushed to after the holiday recess and CMS fully rescinded the Trump era Most Favored Nation Model rule.

President Biden delivered remarks on high drug prices and Reps. Carter and Gonzalez reintroduced their Drug Price Transparency in Medicaid Act to ban spread pricing.

Senate Democrats are expected to meet with the Senate parliamentarian in the coming days and the Supreme Court heard oral arguments from hospitals over 340B payment rates.

The House passed the Build Back Better reconciliation bill.

CMS announced the largest Part B premium increase in 15 years and CBO has started to score the Build Back Better Act, but will not be done until next week.

Congress released their drug pricing reform text and includes a Medicare Part D cap, inflation rebates, and minimal Medicare negotiation in both Part B and Part D.

President Biden announced his Build Back Better framework, which excluded both Medicare negotiation and inflation rebates, to which key Democrats responded with a continued commitment to pass negotiation.

Moderate senators continue to block Medicare negotiation and new PBMs are trying to lower costs for patients as they increase transparency.

The fate of the Democrats' drug pricing plan is uncertain in both chambers and researchers analyzed the effectiveness of the FDA's accelerated approval pathway.

Senator Wyden has confirmed he will not extend Medicare negotiated prices to the commercial market and multiple surveys found drug pricing remains the top voter priority to be included in upcoming packages.

A staff report released by the Committee on Oversight and Reform found Medicare negotiation for 7 drugs could save billions and new polling found 18 million people could not afford at least one of their prescriptions.

Representatives Peters and Schrader introduced their own drug pricing legislation ahead of blocking Medicare negotiation from passing from committee votes to the House floor and drug pricing advocates released new polling data by congressional district.

The Biden administration released their drug pricing plan and House committees have begun to markup legislative text, including prescription drug pricing policies, for the budget reconciliation.

Medicare negotiation may only apply to the Medicare program in the upcoming Senate bill text, but healthcare and employer groups are urging Congress to only pass negotiation if there are protections to the private market.

House leaders have called upon three large drug manufacturers to submit details of their work towards lowering insulin prices and CDER announced a new initiative to create robust pharmaceutical supply chains.

President Biden called for "across the board" Medicare negotiation and a group of five vulnerable Senators filed an amendment for Medicare negotiation in the budget process.

The HHS Office of Inspector General announced an upcoming probe into the accelerated approval pathway and CBO estimated $50.8 billion in savings by delaying Trump's rebate rule.

The infrastructure bill text was released and includes two drug-related offsets and the Senate Judiciary Committee have advanced four bipartisan bills to lower costs and improve access to prescription drugs.

The Senate is continuing to determine what drug pricing provisions will be used to pay for the upcoming infrastructure package and reconciliation bill.

The Senate focused their investigation into anticompetitive behavior on the pharmaceutical industry and vulnerable House Democrats urged Speaker Pelosi and Leader Schumer to include Medicare negotiation in the reconciliation bill.

The Biden administration issued an executive order encouraging competition within the pharmaceutical industry and the House Oversight Committee released their latest staff report from their ongoing pharmaceutical industry investigation.

Senator Rosen introduced legislation to support the nonprofit pharmaceutical sector and Patients for Affordable Drugs exposed Big Pharma's influence over patient advocacy groups.

The Biden administration has issued an RFI to help health plans better negotiate benefits to lower prescription drug costs for patients and five Blue Cross plans announced a new company that will use the plans' data to combat high drug costs.

The Senate Finance Committee Chairman released key principles that will guide their upcoming drug pricing proposal and Majority Leader Schumer announced a $6 trillion budget reconciliation package that is likely to be partially funded by drug savings.

HHS budgeted $60 million to secure the drug supply chain and CIDSA experts continue to speak out about the approval of Aduhelm and the country's drug pricing problem.

The FDA approved the controversial Alzheimer's disease drug and the FTC published a report on how they could potentially prosecute rebate walls.

The House Oversight Committee questioned AbbVie CEO on extreme, unjust price hikes and the House passed bipartisan legislation to make orphan drugs more accessible to patients.

HRSA sent letters to large drug manufacturers warning them of steep fines for curtailing 340B discounts and Minnesota lawmakers introduced a new bill to expand access and coverage of biosimilar products.

The House of Representatives held hearings on lowering drug costs and researchers have recently published studies on the impact that rebates and competition have on out-of-pocket costs.

President Biden's American Families Plan proposal did not include any drug pricing policies, but he has called upon Congress to pass Medicare negotiation this year.

House Democrats reintroduced H.R. 3, which was shortly followed by the Republican's reintroduction of H.R. 19, both of which will be debated in upcoming House committee hearings.

The Biden administration continues to fill health and drug positions as Congress passes bipartisan bills to lower prescription drug prices.

The Congressional Progressive Caucus highlighted Medicare negotiation as a key legislative priority and the FDA issued an industry guidance Q&A on the development of abbreviated new drug applications during the pandemic.

Democrats continue to fight against lingering Trump administration rules and the Congressional Research Service released their overview of the legislative landscape for the 117th Congress to take action on drug pricing.

Democratic policymakers continue to push for Medicare negotiation to lower prescription drug costs at a federal level, as more states move towards state legislation to lower costs.

HHS Secretary Becerra has been confirmed and states are moving to take their own steps to lower drug prices.

The Senate delayed the ban of Medicaid drug rebate caps to 2024 in the most recent COVID-19 relief package and the House is scheduled to vote on drug pricing policies this coming week.

HHS Secretary-nominee has yet to be confirmed and a recent study found that Medicare Part D spends an extra $1.7 billion a year on dispensing brand drugs.

New CBO reports estimated potential savings of removing the Medicaid rebate cap and a federal judge dismissed the 340B case on contract pharmacies.

The House proposed removing Medicaid drug rebate caps as a provision in the COVID-19 relief package and Senator Klobuchar introduced new antitrust legislation that could impact the pharmaceutical industry.

The CBO released their simulation model for the budgetary impact of drug price negotiations and KFF published a new analysis that compares drug price increases to the rate of inflation.

The Biden administration continues to overturn Trump's rules, while state lawmakers introduce their own drug pricing policies.

During the first week of the new Biden administration, President Biden has started to reverse some of Trump's drug pricing work.

The Senate Finance Committee released the findings from a two-year investigation into insulin manufacturers and PBMs while senate leadership has confirmed they will prioritize lowering drug prices.

Multiple stakeholders have highlighted the significant amount of drug pricing reform that the Biden administration will soon be able to make, including freezing harmful rules from the Trump administration that have yet to take effect.

President Trump's Most Favored Nation demo has been slowed down by lawsuits, while his executive order to lower insulin costs has been finalized to go into effect later this month.

CMS published the National Health Expenditures for 2019 and approved a final rule to encourage value-based pricing.

The Supreme Court delivered their ruling on Rutledge v Pharmacy Care Management and a 340B administrative dispute resolution rule was published in the Federal Registrar.

Major trade associations are pushing back against Trump's Most Favored Nation rule and large drug manufacturers continue to limit their participation in the 340B discount program.

Canadian officials responded to Trump's importation rule with their own order and a recent analysis shows how much the Unapproved Drugs Initiative has cost the US health care system.

The Trump administration released two rules to lower prescription drug prices and PhRMA has filed an official complaint regarding the previous importation rule.

Maryland Federal District Court ruled on the Medicaid Drug Rebate Program and the Supreme Court heard arguments to overturn the Affordable Care Act.

Just days after Vice President Biden won the presidential election, a COVID-19 vaccine was announced and the Supreme Court plans to hear arguments on the ACA.

The final rule on price transparency was released and a drug price watchdog reported that generic drug prices are beginning to rise.

The first FDA approved COVID-19 treatment may not be as effective as the high price tag makes it out to be and COVID-19 vaccines are expected to be free for everyone once approved.

The Government Accountability Office (GAO) confirmed they will review the legality of Trump's drug discount cards and Biden announced a drug pricing plan similar to Germany's model.

The Supreme Court heard arguments to allow states to regulate PBMs and the RAND corporation compared insulin prices in the US to 32 other OECD countries.

Drug company CEOs met with House Oversight and Reform Committee to discuss high drug prices; House democrats argued that Trump's $200 drug discount cards are election bribes; and President Trump tested positive for COVID-19.

Most of President Trump's plans to lower drug prices will not take effect until after the election and recent studies show they will do little to actually lower costs.

Congress urged HHS to protect the 340B program while President Trump announced he will lower drug prices with discount cards for seniors.

President Trump released his most favored nation executive order and 340B Health threatened legal action against the drug manufacturers that have limited their 340B discounts.

President Trump plans to meet with pharmaceutical executives to discuss his upcoming executive order, meanwhile drug manufacturers are using his July drug pricing executive orders to defend their withdrawal from the 340B program.

Pharmaceutical executives suggested biased alternatives to President Trump's upcoming most favored nation executive order and a recent AHIP survey found that while individuals support Trump's intention to lower drug prices, they do not support his rebate rule.

The House passed the budget resolution and CBO released a new model to evaluate the impact new legislation has on drug development.